Peptides DB
Research-centric peptide and protocol reference hub

ACE-031 (ACVR2B-Fc) record · updated 20h ago

Muscle & body compMetabolic & appetiteGrade A · human clinicalResearch use only
All 3 studiesJump to the evidenceCompare
What is ACE-031 (ACVR2B-Fc) used for?

ACE-031 is an investigational ACVR2B-Fc fusion protein that acts as a myostatin decoy receptor, studied for muscle-wasting conditions like Duchenne muscular dystrophy.

Primarily researched for · Muscle & body comp

Development stage

where ACE-031 (ACVR2B-Fc) sits between preclinical work and regulatory approval
  1. 1Current
    Preclinical
    Animal / in-vitro work
  2. 2Not reached
    Phase 1
    Safety in humans
  3. 3Not reached
    Phase 2
    Efficacy signal
  4. 4Not reached
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 5 registered trials. It describes the research record, not a recommendation.

Identity
NameACE-031 (ACVR2B-Fc)
Full name—
Sequence—
ClassGH
Research levelEmerging
Discovered byCurated master list · 2026
Pharmacology
Mechanism—
Route—
Half-life—
Time to peak—
Duration—
Extraction confidence—
Effect profile · 0–5
Muscle & body comp: Healing 1.0, Muscle 5.0, Metabolic 2.0, Neuro 1.0, Sleep 0.0, Immune 1.0, Skin 2.0Healing & recovery — 1.0 / 5Muscle & body comp — 5.0 / 5Metabolic & appetite — 2.0 / 5Neuro & mood — 1.0 / 5Inflammation & immune — 1.0 / 5Skin & aesthetics — 2.0 / 5HealingMuscleMetabolicNeuroSleepImmuneSkin1.05.02.01.00.01.02.0
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o mini over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Jul 27, 2026. How this works →
Research stats
Total studies3
Human / animal / cellular0 / 3 / 0
Highest trial phasePreclinical
Years covered2025–2026
Latest study8d ago
Publication history
20252026
Research funding
42 NIH projects · $37.3M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

3 rowsOpen in the library →
StudyTypeYearSummary depth
Gel Electrophoretic Detection of Black Market ACE-031.
FindingIn rat serum, BM ACE-031 was detectable up to 48 h post administration.
Animal2025Full text read0.80
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus).
FindingNot reported in abstract.
Animal2026Partial text0.50
Gel Electrophoretic Detection of Black Market ACE-031.
Finding10 mg/kg body weight administered in rats.
Animal2025Full text read0.80